{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:45:35Z","timestamp":1792043135341,"version":"4.4.0"},"reference-count":44,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: The current availability of monoclonal antibodies against key mediators of type-2 (T2) inflammation has led to a redefinition of the ultimate objectives of severe asthma treatment to a more composite concept of disease remission. Objectives: The aim of this real-life study was to estimate the percentage of patients who achieved clinical remission over 4 years of treatment with benralizumab, and to identify baseline predictors for the achievement of such a composite outcome in the long term. Methods: Data from a 4-year follow-up of 23 patients who were prescribed benralizumab as an add-on therapy because of uncontrolled severe eosinophilic asthma were retrospectively analyzed and compared. Clinical remission was considered to be \u201ccomplete\u201d if oral corticosteroid (OCS) use was not required, there were no exacerbations, an asthma control test (ACT) score \u2265 20 was achieved and a pre-bronchodilation percent predicted a forced expiratory volume in 1 s (FEV1%) \u2265 80%. Clinical remission was considered to be \u201cpartial\u201d if OCS use was not required, plus at least two of the other three aforementioned criteria. Results: The overall percentage of patients who achieved clinical remission was 86.9% after 12 months, and 91.3% after 24 and 48 months of treatment. The rate of complete remission over partial remission increased over time. After 12 months of treatment, 65% of patients fulfilled the criteria for complete remission and 35.0% for partial remission. After 48 months of treatment, 71.4% of patients were in a status of complete remission and 28.6% in a status of partial remission. A long-term composite outcome of complete clinical remission was more likely to be achieved by severe eosinophilic asthma patients with comorbid nasal polyposis, bronchiectasis and osteoporosis, and with OCS dependency, a predicted pre-bronchodilation FEV1% \u2265 80% and a predicted FEF25\u201375% &lt; 65% at baseline. Conclusions: Our real-life experience suggests that treatment with benralizumab may allow the achievement and long-term maintenance of clinical remission in a high percentage of severe eosinophilic asthma patients, up to 4 years of follow-up.<\/jats:p>","DOI":"10.3390\/jcm14062075","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T12:03:06Z","timestamp":1742299386000},"page":"2075","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Long-Term Clinical Remission on Benralizumab Treatment in Severe Eosinophilic Asthma: A Four-Year Real-Life Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4299-7403","authenticated-orcid":false,"given":"Carla Maria Irene","family":"Quarato","sequence":"first","affiliation":[{"name":"Institute of Respiratory Diseases, Policlinico Riuniti of Foggia, 71122 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1202-8567","authenticated-orcid":false,"given":"Pasquale","family":"Tondo","sequence":"additional","affiliation":[{"name":"Institute of Respiratory Diseases, Policlinico Riuniti of Foggia, 71122 Foggia, Italy"},{"name":"Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Lacedonia","sequence":"additional","affiliation":[{"name":"Institute of Respiratory Diseases, Policlinico Riuniti of Foggia, 71122 Foggia, Italy"},{"name":"Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piera","family":"Soccio","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalila","family":"Pescatore","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Lisa","family":"Baccellieri","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Lepore","sequence":"additional","affiliation":[{"name":"Institute of Respiratory Diseases, Policlinico Riuniti of Foggia, 71122 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Foschino Barbaro","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2667-077X","authenticated-orcid":false,"given":"Giulia","family":"Scioscia","sequence":"additional","affiliation":[{"name":"Institute of Respiratory Diseases, Policlinico Riuniti of Foggia, 71122 Foggia, Italy"},{"name":"Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"ref_1","unstructured":"(2024, March 12). 2023 GINA Main Report\u2014Global Initiative for Asthma\u2014GINA. Available online: https:\/\/ginasthma.org\/2023-gina-main-report\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1700765","DOI":"10.1183\/13993003.00765-2017","article-title":"\u201cI have lost in every facet of my life\u201d: The hidden burden of severe asthma","volume":"50","author":"Foster","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.jaci.2015.07.046","article-title":"Acute and chronic systemic corticosteroid-related complications in patients with severe asthma","volume":"136","author":"Lefebvre","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1365-2222.1998.028s5052.x","article-title":"The International Study of Asthma and Allergies in Childhood (ISAAC)","volume":"28","author":"Asher","year":"1998","journal-title":"Clin. Exp. Allergy"},{"key":"ref_5","unstructured":"(2025, March 12). The Global Asthma Report 2022. Available online: https:\/\/globalasthmareport.org\/burden\/burden.php."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","article-title":"The prevalence of severe refractory asthma","volume":"135","author":"Hekking","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jaip.2014.05.005","article-title":"The Prevalence of Severe Asthma and Low Asthma Control Among Danish Adults","volume":"2","author":"Kriegbaum","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"101294","DOI":"10.1016\/j.smim.2019.101294","article-title":"Asthma from immune pathogenesis to precision medicine","volume":"46","author":"Khalaf","year":"2019","journal-title":"Semin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1055\/s-0037-1606217","article-title":"Airway Inflammation and Inflammatory Biomarkers","volume":"39","author":"Lim","year":"2018","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Pelaia, C., Pelaia, G., Crimi, C., Maglio, A., Stanziola, A.A., Calabrese, C., Terracciano, R., Longhini, F., and Vatrella, A. (2022). Novel Biological Therapies for Severe Asthma Endotypes. Biomedicines, 10.","DOI":"10.3390\/biomedicines10051064"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Bafadhel","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1016\/j.jaip.2023.07.041","article-title":"Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus","volume":"11","author":"Canonica","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.anai.2023.08.609","article-title":"Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment","volume":"131","author":"Blaiss","year":"2023","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Caminati, M., Bagnasco, D., Vaia, R., and Senna, G. (2019). New horizons for the treatment of severe, eosinophilic asthma: Benralizumab, a novel precision biologic. Biologics., 13.","DOI":"10.2147\/BTT.S157183"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2004306","DOI":"10.1183\/13993003.04306-2020","article-title":"Novel mechanisms of action contributing to benralizumab\u2019s potent anti-eosinophilic activity","volume":"59","author":"Dagher","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): A randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral Glucocorticoid\u2013Sparing Effect of Benralizumab in Severe Asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): A multicentre, open-label, single-arm study","volume":"10","author":"Gurnell","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12931-023-02439-w","article-title":"Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: Data from the ANANKE study","volume":"24","author":"Vultaggio","year":"2023","journal-title":"Respir. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1016\/j.jaip.2021.06.027","article-title":"FEF25-75% Is a More Sensitive Measure Reflecting Airway Dysfunction in Patients with Asthma: A Comparison Study Using FEF25-75% and FEV1%","volume":"9","author":"Qin","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels (FENO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12325-022-02098-1","article-title":"Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab","volume":"39","author":"Hoyte","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/JAA.S227170","article-title":"Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma","volume":"12","author":"Fitzgerald","year":"2019","journal-title":"J. Asthma Allergy."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"AB13","DOI":"10.1016\/j.jaci.2022.12.045","article-title":"Asthma Clinical Remission with Benralizumab in an Integrated Analysis of the Real-World XALOC-1 Study","volume":"151","author":"Jackson","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12931-023-02539-7","article-title":"Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: Orbe II study","volume":"24","year":"2023","journal-title":"Respir. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/resp.14767","article-title":"Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis","volume":"29","author":"Pelaia","year":"2024","journal-title":"Respirology"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Pini, L., Bagnasco, D., Begh\u00e8, B., Braido, F., Cameli, P., Caminati, M., Caruso, C., Crimi, C., Guarnieri, G., and Latorre, M. (2024). Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study. J. Clin. Med., 13.","DOI":"10.20944\/preprints202402.1390.v1"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S633","DOI":"10.1067\/mai.2000.106155","article-title":"Inflammatory events in asthma: An expanding equation","volume":"105","author":"Lemanske","year":"2000","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/all.14425","article-title":"EAACI Biologicals Guidelines\u2014Recommendations for severe asthma","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00408-022-00579-2","article-title":"Impact of Biologic Therapy on the Small Airways Asthma Phenotype","volume":"200","author":"Chan","year":"2022","journal-title":"Lung"},{"key":"ref_32","first-page":"7461","article-title":"Severe asthma and long-term Benralizumab effectiveness in real-life","volume":"26","author":"Sposato","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e12143","DOI":"10.1002\/clt2.12143","article-title":"Effects of anti-IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real-life multicentre study (BIONIGE)","volume":"12","author":"Contoli","year":"2022","journal-title":"Clin. Transl. Allergy"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1016\/j.jaip.2021.08.004","article-title":"Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study","volume":"9","author":"Nolasco","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Bakakos, A., Schleich, F., and Bakakos, P. (2022). Biological Therapy of Severe Asthma and Nasal Polyps. J. Pers. Med., 12.","DOI":"10.3390\/jpm12060976"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3904\/kjim.2020.022","article-title":"Distinct functions of eosinophils in severe asthma with type 2 phenotype: Clinical implications","volume":"35","author":"Choi","year":"2020","journal-title":"Korean J. Intern. Med."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Santomasi, C., Buonamico, E., Dragonieri, S., Iannuzzi, L., Portacci, A., Quaranta, N., and Carpagnano, G.E. (2023). Effects of benralizumab in a population of patients affected by severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: A real-life study. Acta Bio. Medica Atenei Parm., 94.","DOI":"10.1183\/13993003.congress-2022.575"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Campisi, R., Nolasco, S., Pelaia, C., Impellizzeri, P., D\u2019Amato, M., Portacci, A., Ricciardi, L., Scioscia, G., Crimi, N., and Scichilone, N. (2023). Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12123953"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"190051","DOI":"10.1183\/16000617.0051-2019","article-title":"Is bronchiectasis really a disease?","volume":"29","author":"Shteinberg","year":"2020","journal-title":"Eur. Respir. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.chest.2023.02.009","article-title":"CT Mucus Score and 129Xe MRI Ventilation Defects After 2.5 Years\u2019 Anti-IL-5R\u03b1 in Eosinophilic Asthma","volume":"164","author":"McIntosh","year":"2023","journal-title":"Chest"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/JAA.S196200","article-title":"Severe uncontrolled asthma with bronchiectasis: A pilot study of an emerging phenotype that responds to mepolizumab","volume":"12","author":"Carpagnano","year":"2019","journal-title":"J. Asthma Allergy"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Sposato, B., Bianchi, F., Ricci, A., and Scalese, M. (2023). Clinical Asthma Remission Obtained with Biologics in Real Life: Patients\u2019 Prevalence and Characteristics. J. Pers. Med., 13.","DOI":"10.3390\/jpm13061020"},{"key":"ref_43","first-page":"869","article-title":"Exploring Definitions and Predictors of Severe Asthma Clinical Remission Post-Biologic in Adults","volume":"41","author":"Scelo","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2102583","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: What is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur. Respir. J."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/6\/2075\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:56:11Z","timestamp":1760028971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/6\/2075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14062075"],"URL":"https:\/\/doi.org\/10.3390\/jcm14062075","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]}}}